India orders 660 mln vaccine doses amidst warnings over shortages - media



By Ankur Banerjee and Neha Arora

July 16 (Reuters) - The Indian government has ordered 660 million vaccine doses for August-December, its largest procurement, local news reports said on Friday, as state authorities and health experts warned that shortages could leave millions vulnerable if coronavirus infections surge again.

The federal government aims to inoculate all of the country's estimated 944 million adults by December, a target health experts have said is ambitious, as only 8% of that number is currently vaccinated with the mandatory two doses.

Several states have reported vaccine shortages, with many inoculation centres shut and people having to wait for long hours at others for their shot.

The government has now ordered 375 million more doses of AstraZeneca's AZN.L locally produced Covishield and 285 million doses of Bharat Biotech's homegrown Covaxin, the Economic Times newspaper reported, citing sources.

The health ministry did not immediately respond to a Reuters request for comment.

The Serum Institute of India, which manufactures Covishield, has raised monthly production to about 100 million doses.

The government says Link Bharat Biotech's monthly output will jump to as much as 70 million doses in July/August, from about 10 million doses in April. Production could rise further to nearly 100 million by September, it says.

Bharat Biotech, which has been struggling to raise output of its vaccine, did not respond to a request for an update on its production plans.

"I expect the vaccine shortage to continue and as per the planned vaccine supply, it appears that the daily average for the whole of July will stay below 4 million," said Rijo John, health economist and a professor at the Rajagiri College of Social Sciences in the southern city of Kochi.

After a record 9.1 million doses were administered on June 21, fewer than 4 million doses per day have since been given on an average this month.

A full rollout of Russia's Sputnik V vaccine in India has also been delayed due to a lack of imported supplies. Commercial production of the vaccine in India, however, could begin soon.

India's daily COVID-19 cases have dropped to nearly two-month lows, the country remains the second-highest globally in terms of daily infections.

India reported on Friday 38,949 new coronavirus cases over the last 24 hours, health ministry data showed, taking the nationwide tally above 31 million. Total fatalities were 412,531.



FACTBOX-Worldwide coronavirus cases cross 188.86 million, death
toll at 4,230,242



Reporting by Ankur Banerjee in Bengaluru and Neha Arora in New Delhi; Editing by Clarence Fernandez and Raju Gopalakrishnan

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Gumagamit kami ng cookies para mabigyan ka ng mahusay na karanasan sa aming website. Magbasa pa o palitan ang iyong cookie settings.

Babala sa Risk: Ang iyong kapital ay maaaring malugi. Ang mga produktong naka-leverage ay maaaring hindi para sa lahat. Tingnan ang aming Risk Disclosure.